-
-
-
-
-
-
-
Form SCHEDULE 13G/A Arcturus Therapeutics Filed by: ARK Investment Management LLC
-
-
-
-
-
-
-
Arcturus Therapeutics (ARCT) Reports Q3 Loss of $0.49
-
-
-
-
-
-
-
Arcturus Therapeutics (ARCT) Misses Q2 EPS by $3.55
-
-
-
-
-
-
-
Citi Reiterates Buy Rating on Arcturus Therapeutics (ARCT), PT $44, Opens 90-Day Positive Catalyst Watch
-
-
-
-
-
-
-
Arcturus Therapeutics (ARCT) PT Lowered to $68 at Canaccord Genuity
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Arcturus Therapeutics (ARCT)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Arcturus Therapeutics (ARCT)
-
479,031 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


